Opinion

Video

The Future of RAD-ENZ Combination Therapy

Author(s):

Evan Yu, MD ,Jack R. Andrews, MD

Panelists discuss how regulatory approval of the radium-223 and enzalutamide combination would likely lead to significant guideline updates, particularly in treatment sequencing recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC) with bone-predominant disease and adequate bone marrow function.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Let’s say RAD-ENZ combination treatment receives regulatory approval. Do you foresee any implications for any upcoming guidelines?
      Related Videos
      1 expert in this video
      Resective Surgery and Minimally Invasive Procedures For BPH
      Operationalizing TAR-200 and Other Delivery Systems in Practice
      Operationalizing TAR-200 and Other Delivery Systems in Practice
      Unmet Needs in NMIBC
      Unmet Needs in NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Checkpoint Inhibitors for Treatment of NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      Communication of Treatment Options for High-Risk NMIBC
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      3 experts are featured in this series.
      Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
      1 expert in this video
      BPH: The Patient Journey
      Addressing Remaining Unmet Needs in mCRPC
      Addressing Remaining Unmet Needs in mCRPC
      Use and Sequencing of Novel Treatments in NMIBC
      Use and Sequencing of Novel Treatments in NMIBC
      Related Content
      US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
      February 4th 2025

      FDA Updates in Urology: January 2025

      Patrick Campbell
      A recap of the FDA submissions and regulatory decisions in urology from January 2025.
      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
      January 14th 2025

      Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

      Wayne Kuang, MD Steven Maislos, MD
      Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
      doctor holding a pen talking to patient
      December 14th 2022

      Study finds only half of patients undergoing 24-hour urine tests receive complete testing

      Hannah Clarke
      “One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.
      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
      November 27th 2024

      Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

      Wayne Kuang, MD Bilal Chughtai, MD
      Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
      Doctor discusses treatment information with patient
      October 19th 2022

      Study finds inadequate patient education for scheduled urologic procedures

      Hannah Clarke
      Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.
      First European patient treated for urethral stricture with novel drug-coated balloon catheter
      February 2nd 2021

      First European patient treated for urethral stricture with novel drug-coated balloon catheter

      Jason M. Broderick
      The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.
      © 2025 MJH Life Sciences

      All rights reserved.